Is Cellectis Stock a Good Investment?
Cellectis Investment Advice | CLLS |
- Examine Cellectis' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Cellectis' leadership team and their track record. Good management can help Cellectis navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Cellectis' business and its evolving consumer preferences.
- Compare Cellectis' performance and market position to its competitors. Analyze how Cellectis is positioned in terms of product offerings, innovation, and market share.
- Check if Cellectis pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Cellectis' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Cellectis SA stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Cellectis SA is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Extremely Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Cellectis Stock
Researching Cellectis' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 21.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.97. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cellectis SA recorded a loss per share of 0.41. The entity had not issued any dividends in recent years.
To determine if Cellectis is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Cellectis' research are outlined below:
| Cellectis SA generated a negative expected return over the last 90 days | |
| Cellectis SA has high historical volatility and very poor performance | |
| Cellectis SA may become a speculative penny stock | |
| The company reported the previous year's revenue of 41.51 M. Net Loss for the year was (36.76 M) with profit before overhead, payroll, taxes, and interest of 49.22 M. |
Cellectis uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Cellectis SA. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cellectis' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Cellectis' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 148.83 M.Cellectis' profitablity analysis
The company has Profit Margin (PM) of (0.75) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.7) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.7.Determining Cellectis' profitability involves analyzing its financial statements and using various financial metrics to determine if Cellectis is a good buy. For example, gross profit margin measures Cellectis' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Cellectis' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Cellectis' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cellectis SA. Check Cellectis' Beneish M Score to see the likelihood of Cellectis' management manipulating its earnings.
Basic technical analysis of Cellectis Stock
As of the 21st of March, Cellectis shows the Standard Deviation of 6.29, risk adjusted performance of (0.02), and Mean Deviation of 3.65. Cellectis SA technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Cellectis SA standard deviation and value at risk to decide if Cellectis SA is priced correctly, providing market reflects its regular price of 1.27 per share. Given that Cellectis is a hitting penny stock territory we recommend to closely look at its jensen alpha.Cellectis' Outstanding Corporate Bonds
Cellectis issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cellectis SA uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cellectis bonds can be classified according to their maturity, which is the date when Cellectis SA has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| CELULOSA ARAUCO Y Corp BondUS151191BD46 | View | |
| CELARA 3875 02 NOV 27 Corp BondUS151191BB89 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| US15118JAA34 Corp BondUS15118JAA34 | View |
Understand Cellectis' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Cellectis' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.93) | |||
| Mean Deviation | 3.65 | |||
| Coefficient Of Variation | (3,561) | |||
| Standard Deviation | 6.29 | |||
| Variance | 39.61 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | (0.17) | |||
| Total Risk Alpha | 0.3265 | |||
| Treynor Ratio | (0.94) | |||
| Maximum Drawdown | 38.27 | |||
| Value At Risk | (7.78) | |||
| Potential Upside | 4.49 | |||
| Skewness | 2.94 | |||
| Kurtosis | 12.29 |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.93) | |||
| Mean Deviation | 3.65 | |||
| Coefficient Of Variation | (3,561) | |||
| Standard Deviation | 6.29 | |||
| Variance | 39.61 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | (0.17) | |||
| Total Risk Alpha | 0.3265 | |||
| Treynor Ratio | (0.94) | |||
| Maximum Drawdown | 38.27 | |||
| Value At Risk | (7.78) | |||
| Potential Upside | 4.49 | |||
| Skewness | 2.94 | |||
| Kurtosis | 12.29 |
Consider Cellectis' intraday indicators
Cellectis intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Cellectis stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Cellectis time-series forecasting models is one of many Cellectis' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cellectis' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Cellectis Stock media impact
Far too much social signal, news, headlines, and media speculation about Cellectis that are available to investors today. That information is available publicly through Cellectis media outlets and privately through word of mouth or via Cellectis internal channels. However, regardless of the origin, that massive amount of Cellectis data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Cellectis news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Cellectis relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Cellectis' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Cellectis alpha.
Cellectis Corporate Management
| Dr MBA | Chief Officer | Profile | |
| Steven Doares | North Raleigh | Profile | |
| Valerie Cros | Principal Officer | Profile | |
| Philippe Duchateau | Chief Scientific Officer | Profile | |
| Pascalyne Wilson | Director Communications | Profile | |
| MBA MD | Chief Officer | Profile | |
| Arthur Stril | Interim Officer | Profile |
Additional Tools for Cellectis Stock Analysis
When running Cellectis' price analysis, check to measure Cellectis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectis is operating at the current time. Most of Cellectis' value examination focuses on studying past and present price action to predict the probability of Cellectis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectis' price. Additionally, you may evaluate how the addition of Cellectis to your portfolios can decrease your overall portfolio volatility.